- Home
- GMAB vs JBHT Comparison
GMAB vs JBHT Comparison
Compare GMAB & JBHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- JBHT
- Stock Information
- Founded
- GMAB 1999
- JBHT 1961
- Country
- GMAB Denmark
- JBHT United States
- Employees
- GMAB N/A
- JBHT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- JBHT Trucking Freight/Courier Services
- Sector
- GMAB Health Care
- JBHT Industrials
- Exchange
- GMAB Nasdaq
- JBHT Nasdaq
- Market Cap
- GMAB 12.8B
- JBHT 14.9B
- IPO Year
- GMAB N/A
- JBHT N/A
- Fundamental
- Price
- GMAB $19.88
- JBHT $148.05
- Analyst Decision
- GMAB Buy
- JBHT Buy
- Analyst Count
- GMAB 9
- JBHT 19
- Target Price
- GMAB $39.17
- JBHT $165.26
- AVG Volume (30 Days)
- GMAB 1.5M
- JBHT 1.4M
- Earning Date
- GMAB 05-08-2025
- JBHT 07-15-2025
- Dividend Yield
- GMAB N/A
- JBHT 1.19%
- EPS Growth
- GMAB 85.27
- JBHT N/A
- EPS
- GMAB 17.68
- JBHT 5.52
- Revenue
- GMAB $3,135,137,804.00
- JBHT $12,064,595,000.00
- Revenue This Year
- GMAB $17.69
- JBHT $1.78
- Revenue Next Year
- GMAB $14.81
- JBHT $5.67
- P/E Ratio
- GMAB $1.12
- JBHT $26.83
- Revenue Growth
- GMAB 51.92
- JBHT N/A
- 52 Week Low
- GMAB $17.24
- JBHT $122.79
- 52 Week High
- GMAB $30.41
- JBHT $200.40
- Technical
- Relative Strength Index (RSI)
- GMAB 48.84
- JBHT 62.14
- Support Level
- GMAB $18.89
- JBHT $145.62
- Resistance Level
- GMAB $19.67
- JBHT $153.02
- Average True Range (ATR)
- GMAB 0.49
- JBHT 3.57
- MACD
- GMAB -0.12
- JBHT 2.55
- Stochastic Oscillator
- GMAB 34.61
- JBHT 81.57
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).